文献速递妇科

激素生物标志物对晚期和复发性子宫内膜癌激素治疗反应的影响

Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-19

本研究在16个中心纳入晚期或复发性子宫内膜癌患者,分析治疗前活检组织中雌激素受体和孕激素受体的免疫组化表达及雌激素受体通路活性评分与激素治疗反应的关系。结果显示孕激素受体表达>50%时反应率可达50.0%,联合雌激素受体通路活性检测可进一步提高预测效果,但结论需前瞻性PROMOTE研究验证。

要点

  • 孕激素受体表达>50%与激素治疗反应率50.0%相关。
  • 雌激素受体通路活性评分>15者2年未进展比例为35.8%。
  • 序贯检测孕激素受体和雌激素受体通路活性可改善反应预测。

核心结论

  • 以孕激素受体免疫组化表达50%为切点,并采用孕激素受体表达联合雌激素受体通路活性评分的序贯检测算法,可显著改善子宫内膜癌激素治疗反应的预测。

研究设计与样本

  • 在16个中心识别晚期或复发性子宫内膜癌患者,要求有激素治疗开始前的活检组织且可评估反应。
  • 对肿瘤组织分析雌激素和孕激素受体表达,并使用基于定量聚合酶链反应的信使RNA模型检测雌激素受体通路活性。
  • 主要终点为按实体瘤疗效评价标准定义的反应率(完全缓解和部分缓解),次要终点为临床获益率和无进展生存期。
  • 105例合格病例中81例有足够肿瘤组织且完成反应评估。

主要发现

  • 81例中22例(27.2%)有反应,雌激素受体表达>50%者的反应率为32.3%(95%CI 20.9-43.7)。
  • 孕激素受体表达>50%者的反应率为50.0%(95%CI 35.2-64.8)。
  • 雌激素受体表达>50%者的临床获益率为56.9%(95%CI 44.9-68.9),孕激素受体表达>50%者为75.0%(95%CI 62.2-87.8)。
  • 对孕激素受体表达>50%者应用雌激素受体通路检测,反应率为57.6%(95%CI 42.1-73.1)。
  • 随访2年,孕激素受体表达>50%者中34.3%(95%CI 20-48)未进展,雌激素受体通路活性评分>15者中35.8%(95%CI 20-52)未进展。

临床怎么用

  • 对晚期或复发性子宫内膜癌拟行激素治疗者,可检测孕激素受体免疫组化表达,以50%为切点筛选可能获益人群。
  • 对孕激素受体表达>50%者,可进一步行雌激素受体通路活性评分以优化反应预测。
  • 上述预测策略需在前瞻性PROMOTE研究中验证后方可作为常规推荐。

局限性

  • 结果为回顾性分析,需前瞻性PROMOTE研究验证。
  • 105例合格病例中仅81例有足够组织且完成反应评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. OBJECTIVE: This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. STUDY DESIGN: Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group. Tumor tissue was analyzed for estrogen and progesterone receptor expressions and estrogen receptor pathway activity using a quantitative polymerase chain reaction-based messenger RNA model to measure the activity of estrogen receptor-related target genes in tumor RNA. The primary endpoint was response rate defined as complete and partial response using the Response Evaluation Criteria in Solid Tumors. The secondary endpoints were clinical benefit rate and progression-free survival. RESULTS: Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases. Here, 22 of 81 patients (27.2%) with a response had estrogen and progesterone receptor expressions of >50%, resulting in a response rate of 32.3% (95% confidence interval, 20.9-43.7) for an estrogen receptor expression of >50% and 50.0% (95% confidence interval, 35.2-64.8) for a progesterone receptor expression of >50%. Clinical benefit rate was 56.9% for an estrogen receptor expression of >50% (95% confidence interval, 44.9-68.9) and 75.0% (95% confidence interval, 62.2-87.8) for a progesterone receptor expression of >50%. The application of the estrogen receptor pathway test to cases with a progesterone receptor expression of >50% resulted in a response rate of 57.6% (95% confidence interval, 42.1-73.1). After 2 years of follow-up, 34.3% of cases (95% confidence interval, 20-48) with a progesterone receptor expression of >50% and 35.8% of cases (95% confidence interval, 20-52) with an estrogen receptor pathway activity score of >15 had not progressed. CONCLUSION: The prediction of response to hormonal treatment in endometrial cancer improves substantially with a 50% cutoff level for progesterone receptor immunohistochemical expression and by applying a sequential test algorithm using progesterone receptor immunohistochemical expression and estrogen receptor pathway activity scores. However, results need to be validated in the prospective Prediction of Response to Hormonal Therapy in Advanced and Recurrent Endometrial Cancer (PROMOTE) study.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. van Weelden WJ, Lalisang RI, Bulten J, et al. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. Am J Obstet Gynecol. 2021. PMID: 34019887. doi:10.1016/j.ajog.2021.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。